KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Regeneron Pharmaceuticals (REGN) over the last 9 years, with Sep 2025 value amounting to $3.0 billion.

  • Regeneron Pharmaceuticals' Accumulated Expenses rose 17.32% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 17.32%. This contributed to the annual value of $2.5 billion for FY2024, which is 7.18% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Accumulated Expenses stood at $3.0 billion for Q3 2025, which was up 20.90% from $2.5 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Accumulated Expenses ranged from a high of $3.0 billion in Q3 2025 and a low of $1.5 billion during Q1 2021.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Accumulated Expenses value was $2.4 billion (recorded in 2024), while the average stood at $2.4 billion.
  • In the last 5 years, Regeneron Pharmaceuticals' Accumulated Expenses spiked by 60.54% in 2021 and then fell by 12.84% in 2022.
  • Regeneron Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $2.2 billion in 2021, then decreased by 6.01% to $2.1 billion in 2022, then climbed by 13.68% to $2.4 billion in 2023, then increased by 7.18% to $2.5 billion in 2024, then increased by 17.32% to $3.0 billion in 2025.
  • Its Accumulated Expenses stands at $3.0 billion for Q3 2025, versus $2.5 billion for Q2 2025 and $2.2 billion for Q1 2025.